Genes, autoimmunity and pathogenesis of rheumatic heart disease

Annals of Pediatric Cardiology

Volumn 4, Issue 1, 2011, Pages 13-21

  Guilherme, L ^a   Kohler K F ^a   Postol, E ^a   Kalil, J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Autoimmunity; rheumatic Heart disease; susceptibility genes

Indexed keywords

BACTERIAL ANTIGEN; BETA N ACETYLGALACTOSAMINIDASE; C5A PEPTIDASE; CARDIAC MYOSIN; CYSTEINE PROTEINASE; FICOLIN; HLA DR4 ANTIGEN; HLA DR7 ANTIGEN; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 10; M PROTEIN; STREPTOCOCCUS GROUP A VACCINE; STREPTOCOCCUS VACCINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIMENTIN;

ADAPTIVE IMMUNITY; ALLELE; ANTIGEN BINDING; ARTICLE; CD4+ T LYMPHOCYTE; CROSS REACTION; DISEASE MODEL; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; GROUP A STREPTOCOCCAL INFECTION; HLA SYSTEM; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; MOLECULAR MIMICRY; NONHUMAN; PATHOGENESIS; PROTEIN STRUCTURE; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; STREPTOCOCCUS PYOGENES;

EID: 79955365954     PISSN: 09742069     EISSN: 09745149     Source Type: Journal    
DOI: 10.4103/0974-2069.79617     Document Type: Article

References (86)

1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal disease. Lancet Infect Dis 2005;5:685-94. (Pubitemid 41505357)
2. Mota CC, Aiello DV, Anderson RH. Chronic rheumatic heart disease. In: Anderson RH, Baker EJ, Penny DJ, editors. Pediatric Cardiology. 3rd ed. Philadelphia: Churchill Livingstone/Elsevier; 2009. p. 1091-133.
3. Bland EF, Duckett Jones T. Rheumatic fever and rheumatic heart disease: A 20 years report on 1000 patients followed since childhood. Circulation 1951;4:836-43.
4. Moser M, Leo O. Key concepts in immunology. Vaccine 2010;28:C2-13.
5. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801. (Pubitemid 43261452)
6. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-66.
7. Matsushita M. Ficolins: Complement-activating lectins involved in innate immunity. J Innate Immun 2009;2:24-32.
8. Sorensen R, Thiel S, Jensenius JC. Mannan-bindinglectin- associated serine proteases, characteristics and disease associations. Springer Semin Immunopathol 2005;27:299-319. (Pubitemid 41639883)
9. Runza VL, Schwaeble W, Männel DN. Ficolins: Novel pattern recognition molecules of the innate immune response. Immunobiology 2008;213:297-306. (Pubitemid 351479859)
10. Lynch NJ, Roscher S, Hartung T, Morath S, Matsushita M, Maennel DN, et al . L-ficolin specifically binds to lipoteichoic acid, a cell wall constituent of Grampositive bacteria, and activates the lectin pathway of complement. J Immunol 2004;172:1198-202. (Pubitemid 38113782)
11. Berdeli A, Celik HA, Ozyürek R, Dogrusoz B, Aydin HH. TLR-2 gene Arg753Gln polymorphism is strongly associated with acute rheumatic fever in children. J Mol Med 2005;83:535-41. (Pubitemid 41126069)
12. Zhang P, Cox CJ, Alvarez KM, Cunningham MW. Cutting edge: Cardiac myosin activates innate immune responses through TLRs. J Immunol 2009;183:27-31.
13. de Messias-Reason I, Kremsner PG, Kun JF. Functional haplotypes that produce normal ficolin-2 levels protect against clinical leprosy. J Infect Dis 2009;199:801-4.
14. Messias-Reason IJ, Schafranski MD, Kremsner PG, Kun JF. Ficolin 2 (FCN2) functional polymorphisms and the risk of rheumatic fever and rheumatic heart disease. Clin Exp Immunol 2009;157:395-9.
15. Schafranski MD, Pereira FL, Scherner D, Torres R, Jensenius JC, de Messias-Reason IJ. High-producing MBL2 genotypes increase the risk of acute and chronic carditis in patients with history of rheumatic fever. Mol Immunol 2008;45:3827-31.
16. Ramasawmy R, Spina GS, Faé KC, Pereira AC, Nisihara R, Messias RI, et al. Association of mannose-binding lectin gene polymorphism but not of mannose-binding serine protease 2 with chronic severe aortic regurgitation of rheumatic etiology. Clin Vaccine Immunol 2008;15:932-6. (Pubitemid 351967003)
17. van de Winkel JG, Anderson CL. Biology of human immunoglobulin G Fc receptors. J Leukoc Biol 1991;49:511-24.
18. Yee AM, Phan HM, Zuniga R, Salmon JE, Musher DM. Association between FcgammaRIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin Infect Dis 2000;30:25-8. (Pubitemid 30067057)
19. Berdeli A, Celik HA, Ozyürek R, Aydin HH. Involvement of immunoglobulin FcgammaRIIA and FcgammaRIIIB gene polymorphisms in susceptibility to rheumatic fever. Clin Biochem 2004;37:925-9. (Pubitemid 39209034)
20. Miller LC, Gray ED, Mansour M, Abdin ZH, Kamel R, Zaher S, et al. Cytokines and immunoglobulin in rheumatic heart disease: Production by blood and tonsillar mononuclear cells. J Rheumatol 1989;16:1436-42. (Pubitemid 20015356)
21. Settin A, Abdel-Hady H, El-Baz R, Saber I. Gene polymorphisms of TNF-alpha(-308), IL-10(-1082), IL- 6(-174), and IL-1Ra(VNTR) related to susceptibility and severity of rheumatic heart disease. Pediatr Cardiol 2007;28:363-71. (Pubitemid 47415591)
22. Yeǧin O, Co°kun M, Ertuǧ H. Cytokines in acute rheumatic fever. Eur J Pediatr 1997;156:25-9. (Pubitemid 27000004)
23. Hajeer AH, Hutchinson IV. TNF-alpha gene polymorphism: Clinical and biological implications. Microsc Res Tech 2000;50:216-28. (Pubitemid 30610098)
24. Hernández-Pacheco G, Flores-Domínguez C, Rodríguez- Pérez JM, Pérez-Hernández N, Fragoso JM, Saul A, et al. Tumor necrosis factor-alpha promoter polymorphisms in Mexican patients with rheumatic heart disease. J Autoimmun 2003;21:59-63. (Pubitemid 36871687)
25. Ramasawmy R, Faé KC, Spina G, Victora GD, Tanaka AC, Palácios SA, et al. Association of polymorphisms within the promoter region of the tumor necrosis factor-alpha with clinical outcomes of rheumatic fever. Mol Immunol 2007;44:1873-8.
26. Sallakci N, Akcurin G, Köksoy S, Kardelen F, Uguz A, Coskun M, et al. TNF-alpha G-308A polymorphism is associated with rheumatic fever and correlates with increased TNF-alpha production. J Autoimmun 2005;25:150-4. (Pubitemid 41608559)
27. Morris K, Mohan C, Wahi PL, Anand IS, Ganguly NK. Enhancement of IL-1, IL-2 production and IL-2 receptor generation in patients with acute rheumatic fever and active rheumatic heart disease; a prospective study. Clin Exp Immunol 1993;91:429-36. (Pubitemid 23074148)
28. Narin N, Kütükçüler N, Ozyürek R, Bakiler AR, Parlar A, Arcasoy M. Lymphocyte subsets and plasma IL-1 alpha, IL-2, and TNF-alpha concentrations in acute rheumatic fever and chronic rheumatic heart disease. Clin Immunol Immunopathol 1995;77:172-6.
29. Guilherme L, Cury P, Demarchi LM, Coelho V, Abel L, Lopez AP, et al. Rheumatic heart disease: Proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. Am J Pathol 2004;165:1583-91. (Pubitemid 39435157)
30. Chou HT, Chen CH, Tsai CH, Tsai FJ. Association between transforming growth factor-beta1 gene C-509T and T869C polymorphisms and rheumatic heart disease. Am Heart J 2004;148:181-6.
31. Kamal H, Hussein G, Hassoba H, Mosaad N, Gad A, Ismail M. Transforming growth factor-beta1 gene C-509T and T869C polymorphisms as possible risk factors in rheumatic heart disease in Egypt. Acta Cardiol 2010;65:177-83.
32. Azevedo PM, Bauer R, Caparbo Vde F, Silva CA, Bonfá E, Pereira RM. Interleukin-1 receptor antagonist gene (IL1RN) polymorphism possibly associated to severity of rheumatic carditis in a Brazilian cohort. Cytokine 2010;49:109-13.
33. Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev 2010;21:331-44.
34. Düzgün N, Duman T, Haydardedeoǧlu FE, Tutkak H. Cytotoxic T lymphocyte-associated antigen-4 polymorphism in patients with rheumatic heart disease. Tissue Antigens 2009;74:539-42.
35. Guilherme L, Ramasawmy R, Kalil J. Rheumatic fever and rheumatic heart disease: Genetics and pathogenesis. Scand J Immunol 2007;66:199-207. (Pubitemid 47064375)
36. Bryant PA, Robins-Browne R, Carapetis JR, Curtis N. Some of the people, some of the time: susceptibility to acute rheumatic fever. Circulation 2009;119:742-53.
37. Guedez Y, Kotby A, El-Demellawy M, Galal A, Thomson G, Zaher S, et al. HLA class II associations with rheumatic heart disease are more evident and consistent among clinically homogeneous patients. Circulation 1999;99:2784-90. (Pubitemid 29250025)
38. Stanevicha V, Eglite J, Sochnevs A, Gardovska D, Zavadska D, Shantere R. HLA class II associations with rheumatic heart disease among clinically homogeneous patients in children in Latvia. Arthritis Res Ther 2003;5:R340-6.
39. Visentainer JE, Pereira FC, Dalalio MM, Tsuneto LT, Donadio PR, Moliterno RA. Association of HLA-DR7 with rheumatic fever in the Brazilian population. J Rheumatol 2000;27:1518-20. (Pubitemid 30354055)
40. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000;13:470-511. (Pubitemid 30452618)
41. Guilherme L, Kalil J. Role of autoimmunity in rheumatic fever. Fut Rheumatol 2008;3:161-7. (Pubitemid 351715796)
42. Guilherme L, Kalil J. Rheumatic fever and rheumatic heart disease: Cellular mechanisms leading autoimmune reactivity and disease. J Clin Immunol 2010;30:17-23.
43. Guilherme L, Köhler KF, Kalil L. Rheumatic Heart Disease: Mediation by complex immune events. In: Makoswki GS, editor. Advances in clinical chemistry. 53th ed. Springfield: Elsevier; 2011. p. 31-50.
44. Peterson LK, Fujinami RS. Molecular mimicry. In: Shoenfeld Y, Gershwin ME, Meroni PL, editors. Autoantibodies. 2nd ed. Burlington: Elsevier; 2007. p. 13-9.
45. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1993;11:729-66. (Pubitemid 23115022)
46. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992;359:155-7.
47. Fischetti VA. Streptococcal M protein. Sci Am 1991;264:58-65.
48. Guilerherme L, Kali J, Cunningham M. Molecular mimicry in autoimmune pathogenesis of rheumatic heart disease. Autoimmunity 2006;39:31-9. (Pubitemid 43878518)
49. Guilherme L, Dulphy N, Douay C, Coelho V, Cunha-Neto E, Oshiro SE, et al. Molecular evidence for antigen-driven immune responses in cardiac lesions of rheumatic heart disease patients. Int Immunol 2000;12:1063-74. (Pubitemid 30601369)
50. Cunnigham MW. Autoimmunity and molecular mimicry in the pathogenesis of post streptococcal heart disease. Front Biosci 2003;8:s533-43.
51. Guilherme L, Weidebach W, Kiss MH, Snitcowsky R, Kalil J. Association of human leukocyte class II antigens with rheumatic fever or rheumatic heart disease in a Brazilian population. Circulation 1991;83:1995-8.
52. Raizada V, Williams RC Jr, Chopra P, Gopinath N, Prakash K, Sharma KB, et al. Tissue distribution of lymphocytes in rheumatic heart valves as defined by monoclonal anti-T cells antibodies. Am J Med 1983;74:225-37.
53. Kemeny E, Grieve T, Marcus R, Sareli P, Zabriskie JB. Identification of mononuclear cells and T cell subsets in rheumatic valvulitis. Clin Immunol Immunopathol 1989;52:225-37. (Pubitemid 19177746)
54. El-Demellawy M, El-Ridi R, Guirguis NI, Abdel Alim M, Kotby A, Kotb M. Preferential recognition of myocardial antigens by T lymphocytes from rheumatic heart disease patients. Infect Immun 1997;65:2197-205. (Pubitemid 27237297)
55. Faé KC, da Silva DD, Oshiro SE, Tanaka AC, Pomerantzeff PM, Douay C, et al. Mimicry in recognition of cardiac myosin peptides by heart-intralesional T cell clones from rheumatic heart disease. J Immunol 2006;176:5662-70.
56. Guilherme L, Oshiro SE, Faé KC, Cunha-Neto E, Renesto G, Goldberg AC, et al. T cell reactivty against streptococcal antigens in the periphery mirrors reactivity of heart infiltrating T lymphocytes in rheumatic heart disease patients. Infect Immun 2001;69:5345-51. (Pubitemid 32786466)
57. Yoshinaga M, Figueiroa F, Wahid MR, Marcus RH, Suh E, Zabriskie JB. Antigenic specificity of lymphocytes isolated from valvular specimens of rheumatic fever patients. J Autoimmun 1995;8:601-13.
58. Faé KC, Kalil J, Toubert A, Guilherme L. Heart infiltrating T cell clones from a rheumatic heart disease patient display a common TCR usage and a degenerate antigen recognition pattern. Mol Immunol 2004;40:1129-35. (Pubitemid 38221195)
59. Faé KC, Diefenbach da Silva D, Bilate AM, Tanaka AC, Pomerantzeff PM, Kiss MH, et al. PDIA 3, HS PA5, and Vimentin, proteins identified by 2DE in the valvular tissue, are target antigens of peripheral and heart infiltrating T cells from chronic rheumatic heart disease patients. J Autoimmun 2008;31:136-41.
60. Stockinger B, Veldhoen M, Martin B. Th17 T cells: Linking innate and adaptive immunity. Semin Immunol 2007;19:353-61. (Pubitemid 351274048)
61. Dong C. Diversification of T-helper-cell lineages: Finding the family root of il-17 producing cells. Nat Rev Immunol 2006;6:329-33.
62. Guilherme L, Faé K, Oshiro SE, Kalil, J. Molecular pathogenesis of rheumatic fever and rheumatic heart disease. Expert Rev Mol Med 2005;7:1-15.
63. Unny SK, Middlebrooks BL. Streptococcal rheumatic carditis. Microbiol Rev 1983;47:97-120. (Pubitemid 13081192)
64. Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990;57:250-62. (Pubitemid 20368038)
65. Wegmann KW, Zhao W, Griffin AC, Hickey WF. Identification of myocarditogenic peptides derived from cardiac myosin capable of inducing-experimental allergic myocarditis in the Lewis rat. J Immunol 1994;153:892-900.
66. Li Y, Heuser JS, Kosanke SD, Hemric M, Cunningham MW. Cryptic epitope identified in rat and human cardiac myosin S2 region induces myocarditis in the Lewis rat. J Immunol 2004;172:3225-34. (Pubitemid 38263714)
67. Cunningham MW. T cell mimicry in inflammatory heart disease. Mol Immunol 2004;40:1121-7. (Pubitemid 38221194)
68. Quinn A, Kosanke S, Fischetti VA, Factor SM, Cunningham MW. Induction of autoimmune valvular heart disease by recombinant streptococcal M protein. Infect Immun 2001;69:4072-8. (Pubitemid 32493331)
69. Lymbury RS, Olive CO, Powell KA, Good MF, Hirst RG, Labrooy JT, et al. Induction of autoimmune valvulitis in lewis rats following immunization with peptides from the conserved region of group A streptococcal M protein. J Autoimmun 2003;20:211-7. (Pubitemid 36561486)
70. Gorton D, Blyth S, Gorton JG, Govan B, Ketheesan N. An alternative technique for the induction of autoimmune valvulitis in a rat model of rheumatic heart disease. J Immunol Methods 2010;355:80-5.
71. Gorton D, Govan B, Olive C, Ketheesan N. B- and T-cell responses in group A Streptococcus M-protein- or peptide-induced experimental carditis. Infect Immun 2009;77:2177-83.
72. Cunningham MW, Antone SM, Smart M, Liu R, Kosanke S. Molecular analysis of human cardiac myosin-crossreactive B- and T-cell epitopes of the group A streptococcal M5 protein. Infect Immun 1997;65:3913-23. (Pubitemid 27398159)
73. Steer AC, Batzloff MR, Mulholland, Carapetis JR. Group A streptococcal vaccines: facts versus fantasy. Curr Opin Infect Dis 2009;22:544-52.
74. Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002;70:2171-7. (Pubitemid 34242220)
75. McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharrat GP, et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005;41:1114-22. (Pubitemid 41429473)
76. Dale JB, Penfound T, Chiang EY, Long V, Shulman ST, Beall B. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Clin Diagn Lab Immunol 2005;12:833-6. (Pubitemid 40993282)
77. Bessen D, Fischetti VA. Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A. J Exp Med 1988;167:1945-50.
78. Bessen D, Fischetti VA. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeated region epitopes. J Immunol 1990;145:1251-6. (Pubitemid 20258732)
79. Batzloff MR, Yan H, Davies MR, Hartas J, Lowell GH, White G, et al. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group A Streptococcus. J Infect Dis 2005;192:1450-5. (Pubitemid 41401160)
80. Olive C, Hsien K, Horváth A, Clair T, Yarwood P, Toth I, et al. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides. Vaccine 2005;23:2298-303. (Pubitemid 40341471)
81. Vohra H, Dey N, Gupta S, Sharma AK, Kumar R, McMillan D, et al. M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats. Res Microbiol 2005;156:575-82. (Pubitemid 40615426)
82. Simerska P, Abdel-Aal AB, Fujita Y, Moyle PM, McGeary RP, Batzloff MR, et al . Development of a Liposaccharide-Based Delivery System and Its Application to the Design of Group A Streptococcal Vaccines. J Med Chem 2008;51:1447-52. (Pubitemid 351484799)
83. Olive C, Schulze K, Sun HK, Ebensen T, Horváth A, Toth I, et al. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation. Vaccine 2007;25:1789-97. (Pubitemid 46176331)
84. Guilherme L, Faé KC, Higa F, Chaves L, Oshiro SE, Freschi de Barros S, et al. Towards a vaccine against rheumatic fever. Clin Dev Immunol 2006;13:125-32. (Pubitemid 44950031)
85. Guilherme L, Alba MP, Ferreira FM, Oshiro SE, Higa F, Patarroyo ME, et al. Anti-group A streptococcal vaccine epitope: Structure,stability and its ability to interact with HLA class II molecules. J Biol Chem 2011;286:6989-98.
86. Guilherme L, Postol E, Freschi de Barros S, Higa F, Alencar R, Lastre M, et al. A vaccine against S. pyogenes: Design and experimental immune response. Methods 2009;49:316-21.